The new anti-interleukin-1beta monoclonal antibody, gevokizumab, reduces hs-crp in subjects with type 2 diabetes mellitus

被引：0
|
作者：
Feldstein, J. [1 ]
Davis, S. N. [2 ]
Zayed, H. [1 ]
Whitmore, J. [1 ]
机构：
[1] XOMA LLC, Berkeley, CA USA
[2] Univ Maryland, Baltimore, MD 21201 USA
来源：
EUROPEAN HEART JOURNAL | 2013年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1015 / 1015
页数：1
相关论文
共 50 条
  • [31] A Comparison of hs-CRP Levels in New Diabetes Groups Diagnosed Based on FPG, 2-hPG, or HbA1c Criteria
    Tutuncu, Yildiz
    Satman, Ilhan
    Celik, Selda
    Dinccag, Nevin
    Karsidag, Kubilay
    Telci, Aysegul
    Genc, Sema
    Issever, Halim
    Tuomilehto, Jaakko
    Omer, Beyhan
    JOURNAL OF DIABETES RESEARCH, 2016, 2016
  • [32] A CONNECTION BETWEEN ARTERIAL HYPERTENSION, DYSLIPIDEMIA AND ACTIVITY OF INTERLEUKIN-1BETA AND INTERLEUKIN-6 IN TYPE 2 DIABETES MELLITUS
    Zhuravlyova, L.
    Sokolnikova, N.
    Filonenko, M.
    JOURNAL OF HYPERTENSION, 2019, 37 : E217 - E217
  • [33] Interleukin 1 beta (IL-1β) is a permissive factor for development of type 2 diabetes Mellitus (T2DM)
    Möhlig, M
    Kroke, A
    Spranger, J
    Hoffmamm, K
    Bergmann, MM
    Ristow, M
    Boeing, H
    Pfeiffer, AFH
    DIABETES, 2002, 51 : A29 - A29
  • [34] The effect of dried Ziziphus vulgaris on glycemic control, lipid profile, Apo-proteins and hs-CRP in patients with type 2 diabetes mellitus: A randomized controlled clinical trial
    Niri, Zahra Irannejad
    Shidfar, Farzad
    Jabbari, Masoumeh
    Zarrati, Mitra
    Hosseini, AghaFateme
    Malek, Mojtaba
    Dehnad, Afsaneh
    JOURNAL OF FOOD BIOCHEMISTRY, 2021, 45 (03)
  • [35] Immunomodulatory activity of humanized anti-IL-7R monoclonal antibody RN168 in subjects with type 1 diabetes
    Herold, Kevan C.
    Bucktrout, Samantha L.
    Wang, Xiao
    Bode, Bruce W.
    Gitelman, Stephen E.
    Gottlieb, Peter A.
    Hughes, Jing
    Joh, Tenshang
    McGill, Janet B.
    Pettus, Jeremy H.
    Potluri, Shobha
    Schatz, Desmond
    Shannon, Megan
    Udata, Chandrasekhar
    Wong, Gilbert
    Levisetti, Matteo
    Ganguly, Bishu J.
    Garzone, Pamela D.
    JCI INSIGHT, 2019, 4 (24)
  • [36] Interleukin-1-Beta and Dyslipidemic Syndrome as Major Risk Factors for Thrombotic Complications in Type 2 Diabetes Mellitus
    Badulescu, Oana
    Badescu, Codruta
    Ciocoiu, Manuela
    Badescu, Magda
    MEDIATORS OF INFLAMMATION, 2013, 2013
  • [37] Defective production of interleukin-1 beta in patients with type 2 diabetes mellitus: Restoration by proper glycemic control
    Kousathana, Foteini
    Georgitsi, Marianna
    Lambadiari, Vaia
    Giamarellos-Bourboulis, Evangelos J.
    Dimitriadis, George
    Mouktaroudi, Maria
    CYTOKINE, 2017, 90 : 177 - 184
  • [38] Aerobic exercise training reduces the pre-beta 1 HDL generation and enhances the HDL3 antioxidant role in type 2 diabetes mellitus subjects
    Ribeiro, I. C. D.
    Iborra, R. T.
    Neves, M. Q. T. S.
    Lottenberg, S. A.
    Charf, A. M.
    Nunes, V. S.
    Negrao, C. E.
    Quintao, E. C. R.
    Nakandakare, E. R.
    Passarelli, M.
    ATHEROSCLEROSIS SUPPLEMENTS, 2006, 7 (03) : 527 - 527
  • [39] A new therapeutic approach for type 1 diabetes: Rationale for GNbAC1, an anti-HERV-W-Env monoclonal antibody
    Curtin, Francois
    Bernard, Corinne
    Levet, Sandrine
    Perron, Herve
    Porchet, Herve
    Medina, Julie
    Malpass, Sam
    Lloyd, David
    Simpson, Richard
    DIABETES OBESITY & METABOLISM, 2018, 20 (09): : 2075 - 2084
  • [40] Anti-CD38 autoantibodies:: New markers of β cell autoimmunity in type 1 and type 2 diabetes mellitus
    Mallone, R
    Ortolan, E
    Volante, M
    Pinach, S
    Boscolo, D
    Zanone, MM
    Cavallo-Perin, P
    Malavasi, F
    DIABETES, 2001, 50 : A262 - A262
12345